B+
Bull case
25%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
XBIO
Xenetic BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
40%
Probability
Target price
$1.75
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.65
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-17
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+51.7
Score
AI commentary
News tone is mixed: the DNase update emphasized positive preclinical evidence, royalty growth and study authorization, while the September transaction introduces substantial dilution and execution uncertainty. The $2.19 anchor is dated the acquisition filing day, but the packet lacks a prior close or intraday data, so no defensible event-return attribution is available. Analyst revisions, reliable social coverage, options skew, short interest and employee sentiment were unavailable; the zero sentiment submetrics denote missing evidence rather than neutral readings.
RankAlpha Sentiment Codex - 2026-09-17
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-11-15catalystCash, royalty and transaction-cost updateHigh impact
Xenetic ended Q2 2026 with approximately $6.5 million of cash, reported a roughly $0.9 million quarterly net loss and generated about $1.5 million of first-half royalty revenue. The next financial update could clarify transaction spending, royalty support and financing needs after G&A rose 64% year over year, primarily from strategic-review legal costs. [#SEC-8K-2026-08-07]
2026-12-16eventSantersus acquisition approval and closingHigh impact
Xenetic agreed to acquire all of Santersus, subject to closing conditions and stockholder-related approvals. Santersus holders are expected to own approximately 85% of the combined company's fully diluted shares assuming zero closing net cash, making final transaction terms, net-cash adjustments, approval and completion the dominant near-term event. [#8-K-2026-09-16]
2027-09-17catalystDNase clinical translation milestoneHigh impact
Partner PeriNess received Israeli regulatory and institutional approval for an exploratory study of systemic recombinant human DNase I with anti-CD19 CAR T-cell therapy in large B-cell lymphoma. Study initiation, enrollment or initial clinical evidence could validate the platform, but timing and probability of meaningful data remain uncertain. [#SEC-8K-2026-08-07]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-17 • Updated nightlySource: Internal modelMethodology